Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept
Editas Medicine (Nasdaq: EDIT), a clinical-stage gene editing company, has announced a strategic update webinar scheduled for Tuesday, October 22, 2024, at 8:00 a.m. ET. The webinar will focus on the company's progress towards its 2024 goals, including the significant achievement of establishing in vivo preclinical proof of concept.
The presentation will also cover business development and financial updates. Interested parties can access the live and archived webcast through a provided link or via the Events & Presentations page on the company's website. A replay of the webinar will be available in the Investors section of the Editas Medicine website following the conclusion of the event.
This strategic update offers an opportunity for stakeholders to gain insights into Editas Medicine's recent advancements and future directions in the field of gene editing.
Editas Medicine (Nasdaq: EDIT), una compagnia di editing genetico in fase clinica, ha annunciato un webinar per un aggiornamento strategico programmato per martedì 22 ottobre 2024, alle 8:00 ora dell'Est. Il webinar si concentrerà sui progressi dell'azienda verso gli obiettivi del 2024, incluso il significativo traguardo di stabilire la prova di concetto preclinica in vivo.
La presentazione coprirà anche sviluppi commerciali e aggiornamenti finanziari. Le parti interessate possono accedere al webcast in diretta e registrato tramite un link fornito o tramite la pagina Eventi e Presentazioni sul sito web dell'azienda. Una registrazione del webinar sarà disponibile nella sezione Investitori del sito web di Editas Medicine dopo la conclusione dell'evento.
Questo aggiornamento strategico offre un'opportunità agli stakeholder per ottenere approfondimenti sui recenti progressi di Editas Medicine e le direzioni future nel campo dell'editing genetico.
Editas Medicine (Nasdaq: EDIT), una compañía de edición genética en etapa clínica, ha anunciado un seminario web de actualización estratégica programado para martes 22 de octubre de 2024, a las 8:00 a. m. ET. El seminario web se centrará en el progreso de la empresa hacia sus objetivos de 2024, incluida la importante hazaña de establecer la prueba de concepto preclínica in vivo.
La presentación también abordará actualizaciones de desarrollo comercial y financieras. Las partes interesadas pueden acceder a la transmisión en vivo y grabada a través de un enlace proporcionado o en la página de Eventos y Presentaciones del sitio web de la empresa. Se podrá acceder a una repetición del seminario web en la sección para Inversores del sitio web de Editas Medicine después de la conclusión del evento.
Esta actualización estratégica ofrece una oportunidad para que las partes interesadas obtengan información sobre los avances recientes de Editas Medicine y las direcciones futuras en el campo de la edición genética.
Editas Medicine (Nasdaq: EDIT), 임상 단계의 유전자 편집 회사가 2024년 10월 22일 화요일 오전 8시(동부 표준시)로 예정된 전략적 업데이트 웨비나를 발표했습니다. 이 웨비나는 2024년 목표를 향한 회사의 진행 상황에 초점을 맞추며, in vivo 사전 임상 개념 증명을 확립하는 중요한 성과를 포함합니다.
발표는 사업 개발 및 재무 업데이트도 다룰 것입니다. 관심 있는 당사자는 제공된 링크를 통해 생방송 및 녹화된 웹캐스트에 접속하거나 회사 웹사이트의 이벤트 및 발표 페이지를 통해 접속할 수 있습니다. 이벤트 종료 후, Editas Medicine 웹사이트의 투자자 섹션에서 웨비나 재생이 가능할 것입니다.
이번 전략적 업데이트는 이해관계자들이 Editas Medicine의 최근 발전 사항 및 유전자 편집 분야의 미래 방향에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
Editas Medicine (Nasdaq: EDIT), une entreprise d'édition génétique à un stade clinique, a annoncé un webinaire de mise à jour stratégique prévu pour mardi 22 octobre 2024, à 8h00, heure de l'Est. Le webinaire se concentrera sur les progrès de l'entreprise vers ses objectifs de 2024, y compris l'importante réalisation d'établir une preuve de concept préclinique in vivo.
La présentation couvrira également les mises à jour commerciales et financières. Les parties intéressées peuvent accéder au webinaire en direct et archivé via un lien fourni ou à travers la page Événements et Présentations sur le site web de l'entreprise. Un replay du webinaire sera disponible dans la section Investisseurs du site web d'Editas Medicine après la conclusion de l'événement.
Cette mise à jour stratégique offre aux parties prenantes l'occasion d'obtenir des informations sur les récents progrès d'Editas Medicine et les orientations futures dans le domaine de l'édition génétique.
Editas Medicine (Nasdaq: EDIT), ein Unternehmen für Genbearbeitung in der klinischen Phase, hat ein strategisches Update-Webinar für Dienstag, den 22. Oktober 2024, um 8:00 Uhr ET angekündigt. Das Webinar wird sich auf die Fortschritte des Unternehmens in Richtung seiner Ziele für 2024 konzentrieren, einschließlich des bedeutenden Erfolgs, den in vivo präklinischen Nachweis des Konzepts zu etablieren.
Die Präsentation wird auch Geschäfts- und Finanzupdates behandeln. Interessierte Parteien können über einen bereitgestellten Link oder über die Seite „Veranstaltungen & Präsentationen“ auf der Unternehmenswebsite auf das Live- und das archivierte Webinar zugreifen. Eine Wiederholung des Webinars wird nach Abschluss der Veranstaltung im Investorenbereich der Editas Medicine-Website verfügbar sein.
Dieses strategische Update bietet Stakeholdern die Möglichkeit, Einblicke in die jüngsten Fortschritte von Editas Medicine und die zukünftigen Richtungen im Bereich der Genbearbeitung zu erhalten.
- None.
- None.
Webinar to be held on Tuesday, October 22, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a Company-sponsored webinar on Tuesday, October 22, 2024, at 8:00 a.m. ET to share achievement of in vivo preclinical proof of concept data and business development and financial updates.
Webinar Presentation Details:
The live and archived webcast of the Company’s webinar presentation will be accessible through this webcast link, or through the Events & Presentations page of the “Investors” section of the Company’s website.
A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a clinical-stage gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
FAQ
When is Editas Medicine (EDIT) hosting its strategic update webinar?
What key achievement will Editas Medicine (EDIT) discuss in the webinar?
How can investors access Editas Medicine's (EDIT) strategic update webinar?
What topics will be covered in Editas Medicine's (EDIT) October 2024 webinar?
Will there be a replay available for Editas Medicine's (EDIT) strategic update webinar?
